BioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow BMRN
BioMarin Pharmaceutical Inc. (BMRN) EV/Sales
As of 16 October 2026, BioMarin Pharmaceutical Inc. (BMRN) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 2.9× (May 2026) to 27.8× (July 2015); the current reading is higher than 11% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | (22.18%) |
| FY2024 | 4.4× | (42.77%) |
| FY2023 | 7.6× | (13.41%) |
| FY2022 | 8.8× | 0.08% |
| FY2021 | 8.8× | 3.01% |
| FY2020 | 8.5× | (4.53%) |
| FY2019 | 8.9× | (12.29%) |
| FY2018 | 10.2× | (14.49%) |
| FY2017 | 11.9× | (5.87%) |
| FY2016 | 12.7× | (33.06%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.2× | 29.40% |
| Mar 2026 | 3.3× | (3.86%) |
| Dec 2025 | 3.4× | 4.83% |
| Sep 2025 | 3.2× | (2.86%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PCVX Vaxcyte, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. | 4.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 9.8× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| KRYS Krystal Biotech, Inc. compare | 19.3× |
| IBRX ImmunityBio, Inc. compare | 63.6× |
| KYMR Kymera Therapeutics, Inc. compare | 91.4× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)